Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Prostatic Neoplasms 56Lung Neoplasms 48Leukemia, Myeloid, Acute 44Breast Neoplasms 37Carcinoma, Non-Small-Cell Lung 36Myelodysplastic Syndromes 27Pancreatic Neoplasms 24Leukemia, Lymphocytic, Chronic, B-Cell 24Multiple Myeloma 23Colorectal Neoplasms 23Carcinoma, Renal Cell 22Neoplasm Metastasis 20Melanoma 20Glioblastoma 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Ovarian Neoplasms 17Lymphoma, Large B-Cell, Diffuse 17Brain Neoplasms 16Triple Negative Breast Neoplasms 14Squamous Cell Carcinoma of Head and Neck 12Carcinoma, Hepatocellular 12Lymphoma, Mantle-Cell 11Lymphoma, B-Cell 11Leukemia, Myelomonocytic, Chronic 11Fallopian Tube Neoplasms 11Rectal Neoplasms 10Myeloproliferative Disorders 10Lymphoma, Follicular 10Colonic Neoplasms 10Hematopoietic and Lymphatic System Neoplasm 9

Interventions

enasidenib 1canakinumab 1X-Rays 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Clonal Cytopenia of Undetermined Significance × Specimen Handling × Clear all
NCT05641831 2026-01-02

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
110 enrolled
Classical hematology

Clonal Cytopenia of Undetermined Significance

Data powered by HemOnc (CC BY 4.0) Colophon âš¡